ESR1 and breast cancer: OC inhibited in vitro and in vivo progression of several BC cell lines, including TNBC and the luminal B ER+/HER2+ BC phenotypes and synergized with the selective estrogen receptor modulator tamoxifen [41,42,43,44,45].